Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma

Phase II randomized trial on dose-escalated sorafenib (S) versus best supportive care (BSC) in patients with advanced hepatocellular carcinoma (HCC) with disease progression on prior S treatment.

(2017) T. Pressiani et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of PARP Inhibitors in Cancer Biology and Therapy

(2012) D. Davar et al.   CURRENT MEDICINAL CHEMISTRY

Chronic hypoxia compromises repair of DNA double-strand breaks to drive genetic instability

(2012) R. Kumareswaran et al.   JOURNAL OF CELL SCIENCE

Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?

(2011) Uzma Asghar et al.   JOURNAL OF HEPATOLOGY

A review of PARP inhibitors: from bench to bedside

(2010) C. Underhill et al.   ANNALS OF ONCOLOGY

Mystery of DNA repair: the role of the MRN complex and ATM kinase in DNA damage repair

(2010) Kamila Czornak et al.   JOURNAL OF APPLIED GENETICS

Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways

(2009) X. Liu et al.   MOLECULAR CANCER RESEARCH

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sorafenib in Liver Cancer — Just the Beginning

(2008) Lewis R. Roberts   NEW ENGLAND JOURNAL OF MEDICINE